These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials? Pignatti F; Hemmings R; Jonsson B Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204 [No Abstract] [Full Text] [Related]
24. Effect of crossover on the statistical power of randomized studies. Weinstein GS; Levin B Ann Thorac Surg; 1989 Oct; 48(4):490-5. PubMed ID: 2802849 [TBL] [Abstract][Full Text] [Related]
25. How to design a randomised controlled trial. Brocklehurst P; Hoare Z Br Dent J; 2017 May; 222(9):721-726. PubMed ID: 28496211 [TBL] [Abstract][Full Text] [Related]
27. Does analysis using "last observation carried forward" introduce bias in dementia research? Molnar FJ; Hutton B; Fergusson D CMAJ; 2008 Oct; 179(8):751-3. PubMed ID: 18838445 [No Abstract] [Full Text] [Related]
28. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended. Takada M; Sozu T; Sato T Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032 [TBL] [Abstract][Full Text] [Related]
33. Confounding in health research. Greenland S; Morgenstern H Annu Rev Public Health; 2001; 22():189-212. PubMed ID: 11274518 [TBL] [Abstract][Full Text] [Related]
34. Crossover trials, degrees of freedom, the carryover problem and its dual. Senn SJ; Hildebrand H Stat Med; 1991 Sep; 10(9):1361-74. PubMed ID: 1925167 [TBL] [Abstract][Full Text] [Related]
35. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? Freemantle N BMJ; 2001 Apr; 322(7292):989-91. PubMed ID: 11312237 [No Abstract] [Full Text] [Related]
36. Response to comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias'. Kaizar EE; Vydra TP Stat Med; 2014 Feb; 33(3):538-9. PubMed ID: 24395075 [No Abstract] [Full Text] [Related]
37. Confounding, effect modification, and the odds ratio: common misinterpretations. Shrier I; Pang M J Clin Epidemiol; 2015 Apr; 68(4):470-4. PubMed ID: 25662008 [No Abstract] [Full Text] [Related]
38. INTERMED: a tool for controlling for confounding variables and designing multimodal treatment. Huyse FJ; de Jonge P; Lyons JS; Stiefel FC; Slaets JP J Psychosom Res; 1999 Apr; 46(4):401-2. PubMed ID: 10340241 [No Abstract] [Full Text] [Related]
39. Letter by Al-Ruzzeh and Navia regarding article, "Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery". Al-Ruzzeh S; Navia JL Circulation; 2010 Mar; 121(9):e234. PubMed ID: 20212289 [No Abstract] [Full Text] [Related]
40. Issues of study design and data analysis. D'Agostino RB Inflamm Bowel Dis; 1998 May; 4(2):109-111; discussion 111-3. PubMed ID: 9687216 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]